Encoded Therapeutics, Inc. announced they will use $104 million in Series C financing to advance its lead gene therapy program in Dravet syndrome and its preclinical pipeline. They also unveiled their precision gene therapy platform.
Encoded presented preclinical data on their approach to up-regulate expression in a Dravet mouse model at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in May. The Series C financing has the potential to transform the treatment paradigm for Dravet syndrome and other severe genetic disorders.
Read an abstract for the presentation at ASGCT here. Read the full news release on the financing here.